ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Population-Based Multi-Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population-Based Multi-Omics and Cohort Study Identifying Predictive Biomarkers and Therapeutic Targets for Psoriatic Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Psoriatic disease (PsD) is a chronic inflammatory disease, with significant challenges in early risk stratification and drug development. Integration of proteomic and genomic data provides an unprecedented opportunity to identify predictive biomarkers and therapeutic targets for PsD. Here, through systemic genetic analyses, expression validation, and prospective cohort study, CDSN and PRSS8 were identified as candidate biomarkers and potential therapeutic targets for PsD. Individuals with higher levels of CDSN and PRSS8 were nearly three times more likely to develop PsD compared to the general population. It develops prediction models in adults without PsD at baseline from the UK Biobank. Combining CDSN and PRSS8 with demographics produced desirable predictions for PsD (area under the curve (AUC) = 0.80) and exhibited high specificity. Moreover, PRSS8 and CDSN were both predominantly localized in keratinocytes, and in vivo gene silencing of these proteins significantly reduced PsD-like skin lesions and systemic inflammatory markers. The findings strongly suggested that CDSN and PRSS8 are promising biomarkers for PsD onset and progression, providing a 12-year risk assessment window and potential as novel therapeutic targets. These results had important implications for screening high-risk populations and facilitating early intervention for PsD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.